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Abstract
The growth of both normal and neoplastic tissues is determined by
a balance between cell proliferation and cell death. Thus, under-
standing how these processes not only drive tumour growth
dynamics but also influence therapeutic responsiveness may aid in
the development of more effective cancer treatments. Oestrogen is
a major aetiological factor in the development and progression of
breast cancer, and its effects in driving breast cancer cell prolifer-
ation have been extensively studied. What is less well understood
is how oestrogen’s role as a survival factor influences breast
tumour growth and response to therapy. Recent gene expression
profiling studies in breast cancer cohorts have suggested that
aberrant apoptotic signalling may play a role in responsiveness to
endocrine therapies. Thus, further elucidation of this process may
lead to identification of clinically relevant end-points to determine
and delineate therapeutic response in breast cancer patients.
Introduction
Several recent studies have emphasized the potential of gene
expression profiling to predict both outcome and therapeutic
responsiveness in breast cancer patients [1,2]. Analyses of
the potential function of genes within these predictive gene
signatures have highlighted some of the fundamental
processes that not only are involved in determining the
biological behaviour of breast cancer but also (and perhaps
more importantly from a clinical perspective) influence the
response to therapy. As one may predict, these signatures
are predominated by classes of genes that are involved in cell
cycle regulation and mitogenic signalling. However, there is
emerging evidence that aberrant apoptotic signalling may
also have a role to play, reopening the debate on the impor-
tance of this process in determining endocrine responsive-
ness in breast cancer.
Oestrogen, anti-oestrogens and apoptosis:
the evidence
Unlike its well characterized mitogenic effects, the influence
of oestrogen-mediated survival signalling on the malignant
process in the breast has been relatively understudied.
Oestrogen has direct, inhibitory effects on the apoptotic
machinery in breast cancer cells, including transcriptional
repression of the pro-apoptotic molecules Bak, Bik and
caspase-9 [3] and increased expression of anti-apoptotic
Bcl-2 via oestrogen-response elements in the BCL-2 coding
sequence [4]. There is also evidence of ligand-independent
crosstalk between oestrogen and growth factor intracellular
signalling cascades, particularly those mediated by the erbB
family of receptor tyrosine kinases, which leads to activation
of survival pathways via activation of phosphatidylinositol 3-
kinase [5]. Consequently, regression of breast cancer cell line
(MCF-7 and ZR75-1) derived xenografts after oestrogen
withdrawal or anti-oestrogen treatment is associated with
induction of apoptosis [6,7], and several in vitro studies have
identified components of pro-apoptotic pathways that are
induced by anti-oestrogens in breast cancer cells [8]. These
latter studies have focused predominantly on the intrinsic
apoptotic pathway, and include modulation of expression of
Bcl-2 family members and changes in mitochondrial
membrane potential [8]. However, these effects generally are
observed at ligand concentrations that are unlikely to be
experienced by tumour cells in vivo, and thus the
mechanisms of oestrogen receptor dependent, anti-
oestrogen induced apoptosis and their clinical relevance
remain to be fully defined.
Do apoptotic pathways influence endocrine
responsiveness?
Clinical studies aimed at determining the role played by
apoptosis in the response to endocrine therapies for breast
cancer have often revealed conflicting data. For example,
Reimer and coworkers [9] reported an association between
the death receptor Fas, Fas ligand and resistance to
tamoxifen. Also, others have reported a decrease in expres-
sion of survival genes in breast cancers after neoadjuvant
treatment with aromatase inhibitors [10]. However, studies of
larger cohorts of patients treated with either aromatase
inhibitors or tamoxifen have identified either no significant
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change [11] or, in a separate study, decreased apoptosis
rates following treatment with aromatase inhibitors [12].
These differing results may be due to a number of con-
founding issues. First, there is an inherent difficulty in
accurately monitoring the dynamics of apoptosis in vivo, in
which apoptotic cells are rapidly cleared by macrophages
and neighbouring cells. Second, the interpretation of these
data may also be affected by the assumption that only tumour
regression is an indication of increased apoptosis, whereas
stable disease is maintained predominantly by decreased
proliferation. In fact, studies in animal models have
demonstrated that changes in tumour growth dynamics
similar to those observed in clinically stable disease are
associated with both a reduction in proliferation and an
increase in apoptosis [7,13]. This issue has been addressed
to some extent by examining the apoptotic/mitotic ratio [14],
and data, albeit limited, from clinical studies have
demonstrated that tumour responses to tamoxifen are
positively correlated with this index [15]. However, the
relationship between proliferation and apoptosis can also
depend on the growth conditions of the tumour. For example,
rapidly proliferating tumours can exhibit elevated apoptosis
levels because of an increasingly hypoxic microenvironment.
Third, there has been a reliance on single markers of
apoptosis, such as Bcl-2 expression, as determinants of
response. Although the latter is a transcriptional target of
oestrogen and its expression generally correlates inversely
with the induction of apoptosis, because it is only one
component of a complex apoptotic signalling cascade it may
underestimate the extent of the apoptotic response. In
addition, further functional characterization of many mediators
of apoptotic signalling has revealed that they also play a role
in other cellular processes such as cell cycle progression and
DNA repair, making it difficult to determine whether it is their
apoptotic function per se that is driving the tumour response.
This may partly explain the somewhat counterintuitive reports
of high Bcl-2 expression being associated with better clinical
response to tamoxifen [16], because increased Bcl-2 may
merely reflect a more oestrogen-sensitive cancer.
The advent of gene expression profiling, together with the
more recent introduction of functional classification of
microarray datasets, has enabled researchers to gain greater
insight into the underlying processes that drive neoplastic
growth and influence therapeutic responsiveness and
outcome. It also has the potential to provide an independent
means of assessing the role played by apoptotic signalling in
these events. Although predominated by gene sets involved
in proliferation and mitogenic signalling, several recent
studies in breast cancer cohorts have identified prognostic
signatures that involve cell death and cell survival signalling
[17,18], and a limited number of studies have more
specifically identified signatures that are predictive of
endocrine responsiveness. Jansen and coworkers [19]
identified a predictive gene signature for tamoxifen
responsiveness in a cohort of breast cancer patients with
oestrogen receptor positive recurrent disease. Functional
annotation revealed that about 14% of these genes had a
reported role in mediating cell death or cell survival. Overall,
although both pro-apoptotic and anti-apoptotic changes in
gene expression were observed, the authors concluded that
tamoxifen resistance was associated with an inhibition of
apoptosis. Genes involved in survival signalling, namely
BCL2, BAG1 and Survivin, also formed part of a 16-gene
classifier identified by Paik and colleagues [20] that
predicted the risk for recurrence in patients receiving
adjuvant tamoxifen. However, apoptosis was not identified as
a separate functional cluster in this study, making it difficult to
assess the importance of the apoptotic process in
determining the clinical response.
Although it may be premature to interpret fully the signi-
ficance of these studies, they do suggest that regulators of
survival and apoptosis may have some impact on therapeutic
responsiveness in breast cancer. However, utilizing these
data to provide greater mechanistic insight into the
processes that drive therapeutic responsiveness may require
a hypothesis driven, ‘bottom up’ approach that starts with a
functional end-point and works toward determining its clinical
relevance [2]. Furthermore, given the significant influence of
post-translational mechanisms in regulating apoptotic
signalling cascades, changes at the level of gene expression
are likely to have limited utility or, at best, underestimate the
influence of apoptosis on the response to endocrine
therapies. Clearly, further studies are warranted, adopting an
integrated, multifaceted approach that takes into account the
unique aspects of cell death regulation outlined above, in
order to assess more accurately the impact that apoptosis
has on endocrine responsiveness. Such studies not only will
give further insight into the underlying biology of breast
cancer, but they may also provide useful clinical markers of
therapeutic response and enhance our understanding of the
factors that influence endocrine resistance.
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